(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Bipolar I Disorder
Explore 30 assets in Bipolar I Disorder →Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Joshua Rosenblat
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05339074CT.gov Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression | — | Completed | — | — | — |
NCT05004896CT.gov Ketamine for Treatment-Resistant Bipolar Disorder | — | Completed | — | — | — |
NCT05870501CT.gov Synaptic Imaging and Network Activity in Treatment Resistant Depression | — | Completed | — | — | — |
NCT05249309CT.gov Naturalistic Study of Ketamine in the Treatment of Depression | — | Unknown | — | — | — |
NCT03156504CT.gov The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. | — | Completed | — | — | — |
NCT02593643CT.gov Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bipolar I Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone (this asset) | Joshua Rosenblat | Approved | BB · 68 |
| Lurasidone | Massachusetts General Hospital | P4 | BBB |
| Lithium, Elemental | Alzamend Neuro, Inc. | P4 | BBB |
| Escitalopram | Massachusetts General Hospital | P4 | BBB |
| Olanzapine | Alkermes, Inc. | P4 | BBB |
| Asenapine | Organon and Co | P3 | BBB |
| Lamotrigine | Bristol-Myers Squibb | P4 | BBB |
| Cariprazine | Pakistan Institute of Medical Sciences | P4 | BBB |
| Iloperidone | Vanda Pharmaceuticals | P4 | BBB |
+42 more in the Bipolar I Disorder cohort
Other indications for (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Pain Syndrome | — | P4 | BBB · 74 |
| Post-Traumatic Stress Disorder | — | P4 | BBB · 74 |
| Depressive Disorder | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone in Bipolar I Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2-o-chlorophenyl-2-methylaminocyclohexanone-bipolar-i-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →